Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease Published: 12.09.2024 Navamedic ASA – Mandatory notification of trade by primary insider Published: 09.09.2024 NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS Published: 09.09.2024 Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement Published: 16.08.2024 Navamedic ASA: Invitation to 2024 2nd quarter presentation Published: 12.08.2024 Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe Published: 24.06.2024 FirstPrevious12345NextLast
Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease Published: 12.09.2024
NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS Published: 09.09.2024
Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement Published: 16.08.2024
Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe Published: 24.06.2024
